Showing 231-240 of 279 results for "".
Multiple Eruptive Myxoid Dermatofibromas in Patient With History of HIV
https://practicaldermatology.com/programs/practical-dermatology/multiple-eruptive-myxoid-dermatofibromas-in-patient-with-history-of-hiv/24216/Multiple eruptive dermatofibromas, a rare presentation of dermatofibroma, has been associated with altered immunity such as HIV/AIDS.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-25/23543/The Year in Aesthetics
https://practicaldermatology.com/topics/practice-management/the-year-in-aesthetics/20399/A look at innovations and approvals in cosmetic dermatology in 2017.News
https://practicaldermatology.com/topics/general-topics/news/21339/Biologic Therapies for 2013: Do We Use Them Enough?
https://practicaldermatology.com/topics/psoriasis/biologic-therapies-for-2013-do-we-use-them-enough/22931/Update on Oral Contraceptive Therapy in Acne
https://practicaldermatology.com/topics/general-topics/update-on-oral-contraceptive-therapy-in-acne/21582/While OCPs can be effective against acne, it is important to understand the risks and identify ideal candidates for therapy.New Products
https://practicaldermatology.com/columns/new-products/new-products/21337/A Practical Guide to Modern Melasma Treatment
https://practicaldermatology.com/topics/pigmentary-disorders/a-practical-guide-to-modern-melasma-treatment/67256/Modern management of melasma requires an individualized approach with targeted therapies that incorporate updated knowledge of disease pathogenesis.A Bold New Future for Psoriatic Arthritis Treatments in Dermatology
https://practicaldermatology.com/topics/psoriasis/a-bold-new-future-for-psoriatic-arthritis-treatments-in-dermatology/60989/The current therapeutic landscape highlights the dermatologist’s role in PsA management.The Hidradenitis Suppurativa Therapeutic Pipeline
https://practicaldermatology.com/topics/rare-disease/the-hidradenitis-suppurativa-therapeutic-pipeline/54824/Though treatment options are currently limited, the pipeline for HS therapeutics is active with numerous medications in development.